Zhu and his research team first analyzed the F proteins used in development of four existing RSV vaccines—the commercially available Arexvy, mResvia and Abrysvo, and an experimental vaccine that ...
a vaccine for respiratory syncytial virus that competes with GSK’s Arexvy. GSK alleges that Abrysvo or its “biological active substances” infringe US Patent No. 12,139,512, which was issued Nov. 12 ...
It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they ...
Thankfully, there are currently two RSV vaccines approved by the Food and Drug Administration to help people protect against the virus: Arexvy by GlaxoSmithKline and Abrysvo by Pfizer. The Centers ...
The bottom half of the list featured Reckitt Benckiser’s Mucinex, AstraZeneca’s Breztri Aerosphere, Otsuka’s Rexulti, Haleon’s Robitussin and GSK’s RSV vaccine Arexvy. Robitussin had the lowest ...
According to the analyst, while forecasts for long-acting HIV injectables, Ojjaara in myelofibrosis, and future pipeline projects remain optimistic, potential headwinds for Arexvy & Shingrix, as well ...
TipRanks on MSN21d
GSK downgraded to Hold from Buy at JefferiesWhile GSK’s fundamental value remains compelling, overhangs for the company’s Arexvy and Shingrix vaccines, “more subdued” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback